Torrent Pharmaceuticals logo

Torrent Pharmaceuticals

TORNTPHARM NSE

Key Fundamentals

LargecapPharmaceuticalsHealthcare
Market Cap
1.9L Cr
Volatility
Moderate
P/E Ratio
77.95
EBITDA
₹4,465 Cr
Return on Equity
12.16%
Debt to Equity
1.79
Book Value
₹221.09
EPS
₹49.44
52W High
₹5,250
52W Low
₹3,480.6

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company is expected to give good quarter
  • Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
  • Company has been maintaining a healthy dividend payout of 57.8%

Weaknesses

4
  • Stock is trading at 20.0 times its book value
  • Promoter holding has decreased over last quarter: -7.53%
  • The company has delivered a poor sales growth of 11.8% over past five years.
  • Company might be capitalizing the interest cost

Growth Rate

Revenue Growth
20.34% higher than 3Y
Net Income Growth
11.87% lower than 3Y
Cash Flow Change
16.93% higher than 3Y
ROE
-51.71% lower than 3Y
ROCE
-68.19% lower than 3Y
EBITDA Margin (Avg.)
-0.92% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 2d ago
AI opinion · based on fundamentals
Risk high

Torrent Pharmaceuticals trades at a market cap of ₹1,86,856 Cr with a PE of 86.9x and PB of 22.3x, reflecting steep premium valuations. The company delivers strong return on equity averaging 26% over three years with TTM sales growth accelerating to 33%, though longer-term sales CAGR of 12% over five years is modest. Promoter holding declined 7.53% in the last quarter, a notable governance signal worth monitoring.

Bull Case 7
  • TTM revenue growth has accelerated sharply to 33%, well above the 5-year compounded sales CAGR of 12%, indicating meaningful topline momentum
  • ROE has been consistently high at 27% last year, 26% over 3 years, and 24% over 5 years, reflecting efficient capital deployment
  • Compounded profit growth of 22% over 3 years outpaces the 10-year profit CAGR of 2%, suggesting a structural improvement in profitability
  • Healthy dividend payout ratio of 57.8% demonstrates commitment to returning capital to shareholders, with a current yield of 0.77%
  • Stock price CAGR of 38% over both 1-year and 3-year periods shows sustained market confidence and strong price momentum
  • 10-year ROE of 22% indicates a durable competitive advantage and long-term consistency in generating shareholder returns
  • Company is expected to deliver a good upcoming quarter, which could sustain the current growth trajectory
Bear Case 8
  • PE ratio of 86.9x is extremely elevated relative to pharma sector averages, leaving little margin of safety if growth disappoints
  • Price-to-book of 22.3x (cited as 19.9x in screener data) is exceptionally high, pricing in years of flawless execution
  • Promoter holding decreased by 7.53% in the last quarter, a significant reduction that may signal insider concerns or pledge-related selling
  • 5-year compounded sales growth of only 12% and 10-year sales CAGR of just 8% suggest the underlying business growth rate does not justify an 87x PE multiple
  • 10-year compounded profit CAGR of just 2% highlights that long-term earnings growth has been weak despite recent improvement
  • Possible capitalisation of interest costs could mean reported profits overstate true operating performance
  • Stock price CAGR of 38% over 1 year far outstrips TTM profit growth of 10%, indicating valuation expansion rather than earnings-driven appreciation
  • Dividend yield of 0.77% offers minimal income cushion for investors paying nearly 87x earnings

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 2h ago
Neutral 1
  • Investor meets at top brokerages Sep 10

    Torrent Pharma scheduled investor meetings on Sep 17, 18, and 21, 2026 with Jefferies, Kotak, and JP Morgan across Gurugram and Mumbai. Disclosure filed under SEBI LODR Regulation 30.

TL;DR: Limited recent news flow for Torrent Pharma, with the only development being scheduled investor meetings at three major brokerages in mid-September 2026. No negative catalysts or material positive triggers are visible in the current news cycle. The investor engagement signals management's proactive approach to institutional communication, but the overall trend remains neutral pending further operational or financial updates.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
2,591
2,660
2,732
2,745
2,859
2,889
2,809
2,959
3,178
3,302
3,303
4,197
4,921
Expenses
1,800
1,835
1,863
1,862
1,955
1,950
1,895
1,995
2,146
2,219
2,215
2,841
3,257
Operating Profit
791
825
869
883
904
939
914
964
1,032
1,083
1,088
1,356
1,664
OPM %
31%
31%
32%
32%
32%
32%
33%
33%
32%
33%
33%
32%
34%
Other Income
34
26
55
31
24
-16
33
-42
-37
-40
-23
-83
-33
Interest
103
91
80
80
75
64
57
56
56
48
45
236
305
Depreciation
191
201
213
203
197
198
199
201
201
204
206
508
593
PBT
531
559
631
631
656
661
691
665
738
791
814
529
733
Tax %
29%
31%
30%
29%
30%
31%
27%
25%
26%
25%
22%
31%
23%
Net Profit
378
386
443
449
457
453
503
498
548
591
635
364
566
EPS in Rs
11.17
11.41
13.09
13.27
13.5
13.38
14.86
14.71
16.19
17.46
18.76
10.76
16.72
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
4,636
6,687
5,816
5,950
7,673
7,939
8,005
8,508
9,620
10,728
11,516
13,980
15,723
Expenses
3,616
3,954
4,438
4,601
5,690
5,769
5,524
6,077
6,778
7,360
7,795
9,421
10,532
Operating Profit
1,020
2,733
1,377
1,349
1,983
2,170
2,480
2,431
2,842
3,368
3,721
4,558
5,191
OPM %
22%
41%
24%
23%
26%
27%
31%
29%
30%
31%
32%
33%
33%
Other Income
286
32
223
299
-300
121
57
-288
45
146
-1
-182
-179
Interest
175
184
206
308
504
451
353
255
333
354
252
385
634
Depreciation
191
238
307
409
618
654
658
662
707
808
795
1,119
1,511
PBT
940
2,343
1,088
931
562
1,187
1,526
1,226
1,847
2,352
2,673
2,872
2,867
Tax %
20%
26%
14%
27%
22%
14%
18%
37%
33%
30%
28%
26%
—
Net Profit
751
1,733
934
678
436
1,025
1,252
777
1,245
1,656
1,911
2,138
2,156
EPS in Rs
22.19
51.22
27.59
20.04
12.89
30.28
36.99
22.97
36.79
48.94
56.47
63.92
63.7
Div. Payout %
25%
34%
25%
35%
66%
53%
47%
105%
60%
57%
57%
59%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
85
85
85
85
85
85
85
85
169
169
169
169
Reserves
2,406
3,409
4,266
4,538
4,640
4,739
5,753
5,868
6,029
6,687
7,421
8,219
Borrowings
2,740
2,352
2,510
6,462
6,038
5,784
4,874
4,070
5,369
4,022
3,202
15,026
Other Liabilities
2,589
3,040
2,740
3,159
3,351
3,402
3,363
2,884
3,043
3,627
3,603
20,200
Total Liabilities
7,820
8,886
9,601
14,243
14,113
14,010
14,075
12,906
14,610
14,505
14,396
43,614
Fixed Assets
2,833
2,859
3,688
7,855
7,748
7,533
7,065
6,423
8,121
8,138
7,947
33,191
CWIP
678
1,042
519
647
617
712
889
630
765
361
478
641
Investments
298
780
804
492
353
2
181
226
199
173
156
948
Other Assets
4,011
4,206
4,589
5,249
5,395
5,763
5,940
5,628
5,524
5,834
5,815
8,833
Total Assets
7,820
8,886
9,601
14,243
14,113
14,010
14,075
12,906
14,610
14,505
14,396
43,614
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
810
2,742
1,009
894
1,798
1,393
2,005
1,803
2,368
3,266
2,585
3,023
Investing
-2,113
-869
-798
-4,677
-246
229
-444
-196
-2,335
-160
-549
-12,630
Financing
1,212
-1,435
-193
3,417
-1,314
-1,549
-1,651
-1,781
77
-2,780
-2,298
10,151
Net Cash Flow
-90
437
18
-366
238
73
-89
-174
110
327
-262
544
Free Cash Flow
574
2,150
523
105
1,138
990
1,671
1,607
1,953
2,967
1,991
2,386
CFO/OP
85
121
101
87
105
77
88
91
97
112
86
84
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
125
79
60
77
68
76
69
70
74
63
59
79
Inventory Days
275
314
318
429
318
362
456
368
298
310
334
338
Days Payable
472
523
356
447
345
345
351
250
224
284
239
254
Cash Conversion Cycle
-71
-130
21
59
42
93
174
188
147
89
154
163
Working Capital Days
29
-1
28
-80
-62
-52
-5
7
-33
-27
7
-26
ROCE %
27%
48%
19%
13%
13%
15%
17%
19%
20%
23%
27%
15%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Torrent Pharmaceuticals insights

57 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Shareholding Pattern

Others1.38%Govt.0.10%Promot.68.31%Public5.04%DIIs9.73%FIIs15.44%As ofJun 2026

Documents

Frequently Asked Questions about Torrent Pharmaceuticals

What does Torrent Pharmaceuticals Ltd do?
Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1] It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesse...
Where is Torrent Pharmaceuticals Ltd (TORNTPHARM) listed?
Torrent Pharmaceuticals Ltd trades as TORNTPHARM on the NSE and under code 500420 on the BSE.
Which sector does Torrent Pharmaceuticals Ltd belong to?
Torrent Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd has a market capitalisation of ₹1,86,856 Cr, which places it in the Large Cap band.
What is the PE ratio of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd trades at a PE ratio of 77.95, on earnings per share of ₹49.44, against a book value of ₹221.09 per share.
What is the 52-week high and low of Torrent Pharmaceuticals Ltd?
Over the last 52 weeks Torrent Pharmaceuticals Ltd has traded between ₹3,480.6 and ₹5,250.
Does Torrent Pharmaceuticals Ltd pay dividends?
Torrent Pharmaceuticals Ltd has a dividend yield of 0.77%.
What is the Return on Equity (ROE) of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd reported a return on equity of 12.16%. Its debt-to-equity ratio is 1.79.

Company Information

Torrent Pharmaceuticals Ltd is one of the leading Indian Pharmaceutical Company engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations.[1] It is the flagship company of Torrent Group which also has presence in power and city gas distribution businesses.[2]

Website torrentpharma.com
CEO Mr. Aman Mehta
Employees 17,059
Listed 2002-11-25
Face Value ₹ 5
Issued Size 33,84,45,440

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TORNTPHARM.md for Torrent Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List